In addition to being a new standard of care for treatment-naïve advanced EGFR mutant NSCLC, it has been proven to be effective in adjuvant settings in treating early-stage EGFR-mutant NSCLC after surgery [75]. Here, EGFR is linked to non-small cell lung carcinoma.